Market Closed -
Nasdaq
04:00:00 2024-12-06 pm EST
5-day change
1st Jan Change
56.97 USD
+1.75%
-0.45%
+3.32%
Ani Pharmaceuticals Insider Sold Shares Worth $1,941,442, According to a Recent SEC Filing
Nov. 29
MT
Ani Pharmaceuticals Insider Sold Shares Worth $375,050, According to a Recent SEC Filing
Nov. 18
MT
ANI Pharmaceuticals, Inc., Q3 2024 Earnings Call, Nov 08, 2024
Nov. 08
ANI Pharmaceuticals' Q3 Adjusted Earnings, Net Revenue Rise; Fiscal 2024 Outlook Lifted
Nov. 08
MT
(ANIP) ANI PHARMACEUTICALS Expects Fiscal Year 2024 EPS Range $4.90 - $5.05
Nov. 08
MT
Earnings Flash (ANIP) ANI PHARMACEUTICALS Reports Q3 Revenue $148.3M
Nov. 08
MT
Earnings Flash (ANIP) ANI PHARMACEUTICALS Posts Q3 EPS $1.34
Nov. 08
MT
ANI Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024
Nov. 08
CI
ANI Pharmaceuticals, Inc. Revises Earnings Guidance for the Year 2024
Nov. 08
CI
ANI Pharmaceuticals Launches Estradiol Gel Following US FDA's Final Approval for Abbreviated New Drug Application
Oct. 25
MT
ANI Pharmaceuticals, Inc. Announces the FDA Approval and Launch of Estradiol Gel, 0.06%
Oct. 25
CI
Truist Raises Price Target on ANI Pharmaceuticals to $62 From $60, Keeps Hold Rating
Oct. 22
MT
Piper Sandler Initiates Coverage on ANI Pharmaceuticals With Overweight Rating, $68 Price Target
Oct. 11
MT
Wall Street Set to Open Lower Thursday; Weekly Initial Jobless Claims Rise Higher Than Expected
Oct. 03
MT
Sector Update: Health Care Stocks Edge Higher Premarket Thursday
Sep. 26
MT
ANI Pharmaceuticals Says FDA Approved Generic Version of Nizoral Anti-Dandruff Shampoo
Sep. 26
MT
Top Premarket Gainers
Sep. 17
MT
ANI Pharmaceuticals Completes Purchase of Alimera Sciences, Sees 'Substantially Higher' Earnings After Deal
Sep. 16
MT
ANI Pharmaceuticals, Inc. completed the acquisition of Alimera Sciences, Inc. from Caligan Partners Master Fund LP and Caligan Partners Master Fund LP, managed by Caligan Partners, LP and others.
Sep. 15
CI
ANI Pharmaceuticals Launches Oral Solution of Promethazine Hydrochloride and Dextromethorphan Hydrobromide
Sep. 13
MT
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Wednesday as Looming CPI Data Likely to Provide Rate-Cut Clues
Sep. 11
MT
ANI Pharmaceuticals, Alimera Sciences to Close Merger Next Week
Sep. 11
MT
Truist Downgrades ANI Pharmaceuticals to Hold From Buy, Cuts Price Target to $60 From $80
Sep. 11
MT
Sector Update: Health Care Stocks Advance Late Afternoon
Sep. 10
MT
Alimera Sciences Sues ANI Pharmaceuticals for Delays in Merger Close
Sep. 10
MT
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
ANIP: Dynamic Chart
ANI Pharmaceuticals, Inc. is a diversified biopharmaceutical company, which serves patients in need by developing, manufacturing and marketing branded and generic prescription pharmaceutical products, including for diseases with high unmet medical need. The Company is focused on delivering sustainable growth by scaling up its Rare Disease business through its lead asset, Purified Cortrophin Gel, as well as its generics business with enhanced research and development capabilities. Its three pharmaceutical manufacturing facilities, of which two are located in Baudette, Minnesota, and one is located in East Windsor, New Jersey, are together capable of producing oral solid dose products, as well as semi-solids, liquids and topicals, controlled substances, and potent products. The Company has a commercial portfolio of approximately 118 products with a variety of indications and a robust portfolio of pipeline products.
More about the company
Last Close Price
56.97 USD
Average target price
78.40 USD
Spread / Average Target
+37.62%
Consensus
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1